BBUSvsGNOM
JPMorgan BetaBuilders U.S. Equity ETF against Global X Genomics & Biotechnology ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BBUS | GNOM | |
|---|---|---|
| Expense ratio | 0.020% | 0.50% |
| Assets | $9.3B | $85M |
| Net flow, 1 month | +$242M | — |
| Net flow, 1 year | +$2.6B | — |
| Return, YTD | +12.7% | +53.2% |
| Return, 1 year | +14.6% | +71.9% |
| Avg daily volume | 260K | 36K |
| Holdings | 575 | 41 |
| Listed | Mar 11, 2019 | Apr 5, 2019 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS